Phase 2 Sickle Cell Disease Trial, Recruiting (NCT06260891)

Phase 2 Sickle Cell Disease Trial, Recruiting NCT06260891 Sponsor: University of California, San Francisco Condition: Sickle Cell Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06260891 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Sickle Cell Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 15 to 40 years old
People who have been diagnosed with Sickle Cell Disease (either the SS type or the S Beta-zero Thalassemia type)
People who are currently in a "steady state," meaning at least 2 weeks have passed since their last pain crisis
Both males and females are eligible

Who may not be able to join:

People who are currently taking any supplement that contains zinc and are unable or unwilling to stop taking it for 3 months before the trial begins
People whose Vitamin D levels (specifically 25-Hydroxy Vitamin D) are below 20 ng/mL, which is considered low
People who receive frequent blood transfusions (more than 8 per year) and also have too much iron stored in their body (based on liver iron levels or blood ferritin levels being above certain thresholds)
People who are unable to swallow pills or who cannot take a daily supplement as directed
People who are currently taking part in another clinical trial involving an investigational (not yet approved) drug
People who have been diagnosed with chronic kidney disease where kidney function is significantly reduced (confirm with trial site for specific test values)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ellen Fung, PhD, University of California, San Francisco

Phone: 480-793-2162

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06260891

Sponsor: University of California, San Francisco

Phase: Phase 2

Status: Recruiting

Condition: Sickle Cell Disease

Trial contact: 480-793-2162

More information: https://clinicaltrials.gov/study/NCT06260891

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 15 to 40 years old
People who have been diagnosed with Sickle Cell Disease (either the SS type or the S Beta-zero Thalassemia type)
People who are currently in a "steady state," meaning at least 2 weeks have passed since their last pain crisis
Both males and females are eligible

Who may not be able to join:

People who are currently taking any supplement that contains zinc and are unable or unwilling to stop taking it for 3 months before the trial begins
People whose Vitamin D levels (specifically 25-Hydroxy Vitamin D) are below 20 ng/mL, which is considered low
People who receive frequent blood transfusions (more than 8 per year) and also have too much iron stored in their body (based on liver iron levels or blood ferritin levels being above certain thresholds)
People who are unable to swallow pills or who cannot take a daily supplement as directed
People who are currently taking part in another clinical trial involving an investigational (not yet approved) drug
People who have been diagnosed with chronic kidney disease where kidney function is significantly reduced (confirm with trial site for specific test values)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of California, San Francisco

Registry

ClinicalTrials.gov

Start date

14 February 2026

Est. completion

31 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Biomarker of Bone Formation (PINP); Biomarker of Bone Resorption (CTx)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov